Inventiva (NASDAQ:IVA) Stock Price Down 6.9% – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price fell 6.9% on Thursday . The stock traded as low as $6.13 and last traded at $6.17. 233,574 shares traded hands during trading, a decline of 29% from the average session volume of 326,927 shares. The stock had previously closed at $6.63.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. HC Wainwright set a $24.00 target price on Inventiva and gave the company a “buy” rating in a research report on Wednesday, January 28th. Guggenheim lowered their target price on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. UBS Group initiated coverage on Inventiva in a research note on Wednesday, January 7th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Barclays started coverage on shares of Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $17.00.

Inventiva Stock Down 2.9%

The business’s 50 day moving average is $6.18 and its 200 day moving average is $5.35.

Institutional Investors Weigh In On Inventiva

A number of hedge funds have recently made changes to their positions in IVA. Creative Planning bought a new stake in Inventiva during the second quarter valued at about $32,000. Virtu Financial LLC bought a new position in Inventiva in the fourth quarter worth about $60,000. XTX Topco Ltd purchased a new stake in shares of Inventiva during the fourth quarter valued at about $84,000. Cerity Partners LLC bought a new stake in shares of Inventiva in the 4th quarter valued at about $93,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Inventiva in the 3rd quarter worth approximately $116,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.